Clin Ther. 2013 Aug;35(8):1076-81. doi: 10.1016/j.clinthera.2013.07.426.
International studies suggest almost half of all major coronary episodes annually occur in survivors of acute coronary syndrome (ACS).
A greater focus on medium- and long-term ACS management and adherence to proven therapies is essential if out-of-hospital reductions in mortality and morbidity are to be optimized.
A national panel of clinical and research opinion leaders in ACS care met for 2 days to set future priorities in health care delivery.
Lifestyle, control of risk factors, and prescription of pharmacological therapies can improve the course of coronary heart disease (CHD) by reducing all-cause and cardiovascular mortality by 15% to 25%. All ACS patients stand to benefit from rehabilitation and systematic secondary prevention, however, underutilization and suboptimal adherence to rehabilitation and secondary prevention measures persist globally.
A range of new initiatives in Australia and elsewhere indicate that time is ripe for change to improve the uptake of preventative treatments in patients after ACS. Key universal drivers of delivering best evidence practice for medium- to long-term care after ACS are economics and locality.
Health-service redesign involving all stakeholders will be integral to increasing access, uptake, and adherence to lifestyle, control of risk factors, and pharmacologic therapies shown to improve cardiovascular outcomes.
国际研究表明，每年近一半的主要冠心病发作发生在急性冠脉综合征（ACS）幸存者中。
如果要优化院外死亡率和发病率的降低，就必须更加关注 ACS 的中长期管理和遵循已证实的治疗方法。
ACS 护理方面的一组国家临床和研究意见领袖进行了为期两天的会议，以确定未来医疗保健服务的优先事项。
生活方式、控制危险因素和开具药物治疗可以通过降低全因和心血管死亡率 15%至 25%来改善冠心病（CHD）的病程。所有 ACS 患者都可以从康复和系统二级预防中受益，然而，全球范围内康复和二级预防措施的利用率低且不达标。
澳大利亚和其他地方的一系列新举措表明，现在是时候改变现状，提高 ACS 患者预防治疗的采用率了。推动 ACS 后中长期最佳证据实践的通用驱动因素是经济和地理位置。
涉及所有利益相关者的卫生服务重新设计对于增加生活方式、控制危险因素和药物治疗的可及性、采用率和达标率至关重要，这些治疗方法已被证明可以改善心血管结局。
